

STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE THREE MONTHS ENDED JUNE 30, 2023

(Rs. In crores)

Particulars	Three months ended June 30, 2023	Three months ended March 31, 2023	Corresponding Three months ended June 30, 2022	For the previous year ended March 31, 2023
	(Unaudited)	(Refer note 9)	(Refer note 5,6 and 10)	(Audited)
Revenue from operations	1,748.85	2,163.58	1,481.99	7,081.55
Other Income (Net)	38.31	24.50	71.85	225.11
Total Income	1,787.16	2,188.08	1,553.84	7,306.66
Expenses				
Cost of Materials Consumed	417.40	486.76	411.83	1,682.46
Purchase of Stock-in-Trade	268.19	202.45	195.56	952.20
Changes in inventories of finished goods, work-in-progress and stock-in-trade	(58.86)	150.51	(33.06)	68.64
Employee benefits expense	495.54	473.53	460.54	1,896.35
Finance Costs	118.52	104.25	62.30	344.18
Depreciation and amortisation expense	173.61	184.41	161.66	676.69
Other Expenses (Net)	494.26	499.06	430.04	1,853.66
Total Expenses	1,908.66	2,100.97	1,688.87	7,474.18
Profit/(Loss) before share of net profit of associates, exceptional items and tax	(121.50)	87.11	(135.03)	(167.52)
Share of net profit of associates	14.39	7.78	19.89	54.33
Profit/(Loss) after share of net profit of associates before exceptional item and tax	(107.11)	94.89	(115.14)	(113.19)
Exceptional items (Refer Note 7)	-	-	-	(6.96)
Profit/(Loss) after share of net profit of associates and before tax	(107.11)	94.89	(115.14)	(120.15)
Tax Expense				
(1) Current Tax (including prior year taxes)	24.69	32.67	20.87	110.40
(2) Deferred Tax, net	(33.22)	12.11	(26.96)	(44.09)
Net Profit/(Loss) after tax	(98.58)	50.11	(109.05)	(186.46)
Other Comprehensive Income/(Loss) (OCI), net of tax expense				
A. Items that will not be subsequently reclassified to profit or loss				
Remeasurement of Post Employment Benefit Plans	(5.03)	0.33	(3.11)	(3.44)
Less: Income Tax Impact on above	1.27	(0.08)	0.75	0.87
B. Items that will be subsequently reclassified to profit or loss				
(a) Deferred gains / (losses) on cash flow hedge	6.04	35.59	(64.33)	(20.75)
(b) Exchange differences on translation of foreign operations	23.76	(12.15)	80.70	210.10
Less: Income Tax Impact on above	0.57	(6.41)	7.88	(10.98)
Total Other Comprehensive Income/(Loss) (OCI) for the period, net of tax expense	26.61	17.28	21.89	175.80
Total Comprehensive Income/(Loss) for the period	(71.97)	67.39	(87.16)	(10.66)
Paid-up Equity Share Capital (Face Value of Rs. 10/- each)	1,193.32	1,193.32	1,185.91	1,193.32
Other Equity				5,580.18
Earnings Per Equity Share (EPS) (Face Value of Rs. 10/- each) (not annualised for the quarters)				
a) Basic EPS for the period/year (Rs.)	(0.83)	0.42	(0.92)	(1.57)
b) Diluted EPS for the period/year (Rs.)	(0.83)	0.42	(0.92)	(1.57)

See accompanying notes to the unaudited Consolidated financial results



Piramal Pharma Limited
CIN : U24297MH2020PLC338592

Registered Office: Gr. Flr. Piramal Ananta, Agastya Corporate Park, Opp Fire Brigade, Kamani Junction, LBS Marg, Kurla (West), Mumbai – 400070 India
T +91 22 3802 3000 / 4000
piramal.com



Notes:
1 Standalone Information:
(Rs. In Crores)

Particulars	Three months ended June 30, 2023	Three months ended March 31, 2023	Corresponding Three months ended June 30, 2022	For the previous year ended March 31, 2023
1. Total Income	873.11	1,117.46	853.08	3,784.29
2. Profit/(Loss) before tax	(40.90)	65.64	(24.60)	123.69
3. Profit/(Loss) after tax	(33.36)	41.70	(17.12)	69.50

2 The unaudited consolidated financial results for the three months ended June 30, 2023 have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meeting held on August 03, 2023. The Statutory auditors of the Company have carried out a limited review of these results.

3 The Consolidated Financial Results of the company for the three months ended June 30, 2023 have been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards as prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India.

4 The Committee of Directors (Rights Issue) at its meeting held on July 27, 2023 has inter alia considered and approved the rights issue of 129,629,630 fully paid-up Equity Shares of Rights issue price of ₹81 per equity share [including a premium of ₹ 71 per Equity Share] for amount aggregating up to ₹1,050 crores. Subsequently, Rights Issue Letter of Offer (LoF) was filed on July 28, 2023 with Securities and Exchange Board of India (SEBI), BSE Limited (BSE) and National Stock Exchange of India Limited (NSE).

5 During the previous year, the Composite Scheme of Arrangement between the Piramal Pharma Limited ("the Company"), Piramal Enterprises Limited ('PEL'), Convergence Chemicals Private Limited ('CCPL'), Hemmo Pharmaceuticals Private Limited ('HPPL'), PHL Fininvest Private Limited ('PFPL') and their respective shareholders and creditors ('Scheme'), submitted pursuant to the approval of Board of Directors of the Company at their meeting held on October 7, 2021, was approved by National Company Law Tribunal on August 12, 2022 ("approval date") with an appointed date of 1st April, 2022 ("appointed date"). Effect of the Scheme resulted into,

a) Business combination accounting following the purchase price allocation of assets and liabilities acquired of Demerged Undertaking (as defined in the Scheme) in accordance with Ind-AS 103 'Business Combination', cancellation of 94,72,49,806 (nos.) equity shares of face value of Rs. 10 each issued to PEL and fresh issuance of 95,46,54,800 (nos.) equity shares of face value of Rs. 10 each to the shareholders of PEL, and elimination of intercompany transactions, (including dividend) for the interim period (i.e. from appointed date to approval date).

b) Amalgamation of CCPL and HPPL, wholly owned subsidiaries, using 'the pooling of interest method', as if the amalgamation had occurred on 1st April, 2021 or from the date on which the Company acquired control over these subsidiaries, whichever is later, in line with Appendix-C of Ind-AS 103. Subsequently, the Company received approval on October 19, 2022 for listing application filed with Securities and Exchange Board of India (SEBI), BSE Limited (BSE) and National Stock Exchange of India Limited (NSE).

6 During the previous year, the inventory of the demerged undertaking acquired by the company (consequent to the composite scheme being effective) included certain inventory that was sold with margin by the company to the demerged undertaking and lying in inventory as on the appointed date. In accordance with the IND AS 103 "Business combination" the company on acquisition had ascribed a fair value to the inventory (provisional) being the price at which the company sold the inventory. Consequently, the margins had been impacted on sale of the said products.

7 In the Consolidated Financial Results, 'Exceptional items' include:

(Rs. In Crores)

Particulars	Three months ended June 30, 2023	Three months ended March 31, 2023	Corresponding Three months ended June 30, 2022	For the previous year ended March 31, 2023
Certain transaction cost related to note 5	-	-	-	(6.96)
Total	-	-	-	(6.96)

8 The group operates in only one segment and hence segment disclosure is not applicable.

9 The figures for the last quarter of the previous financial year are the balancing figures between audited figures in respect of the full financial year and the published year to date figures upto the end of third quarter of the previous financial year which were subjected to limited review by statutory auditors.


10 Previous period/s/ year's figures have been regrouped/reclassified, wherever necessary.



August 3, 2023, Mumbai



For **PIRAMAL PHARMA LIMITED**


Nandini Piramal
Chairperson

Piramal Pharma Limited
CIN : U24297MH2020PLC338592

Registered Office: Gr. Flr. Piramal Ananta, Agastya Corporate Park, Opp Fire Brigade, Kamani Junction, LBS Marg, Kurla (West), Mumbai – 400070 India

T +91 22 3802 3000 / 4000

piramal.com

INDEPENDENT AUDITOR'S REVIEW REPORT ON INTERIM CONSOLIDATED FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF PIRAMAL PHARMA LIMITED

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of **PIRAMAL PHARMA LIMITED** (the "Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), and its share of the net profit after tax and total comprehensive income of its associates for the three months ended June 30, 2023 (the "Statement"), being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard (Ind AS) 34 "Interim Financial Reporting", prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder, other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements ("SRE") 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India ("ICAI"). A review of interim financial information consists of making inquiries, primarily of Parent's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of the entities listed in Annexure I.
5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.



**Deloitte
Haskins & Sells LLP**

6. We did not review the interim financial information of ten subsidiaries included in the unaudited consolidated financial results, whose interim financial information reflect total revenues of Rs. 1,028.98 crores, total net profit after tax of Rs. 2.96 crores and total comprehensive income of Rs. 29.80 crores for the three months ended June 30, 2023, as considered in the Statement. These interim financial information have been reviewed by other auditors whose reports have been furnished to us and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.

Our conclusion on the Statement is not modified in respect of this matter.

7. The unaudited consolidated financial results includes the interim financial information of seven subsidiaries which have not been reviewed or audited by their auditors, whose interim financial information reflect total revenue of Rs. 40.05 crores, total loss after tax of Rs. 1.77 crores and total comprehensive loss of Rs. 1.91 crores for the three months ended June 30, 2023, as considered in the Statement. The unaudited consolidated financial results also includes the Group's share of loss and total comprehensive loss of Rs. 0.52 crores for the three months ended June 30, 2023, as considered in the Statement, in respect of one associate, based on their interim financial information which have not been reviewed by their auditor. According to the information and explanations given to us by the Management, these interim financial information are not material to the Group.

Our conclusion on the Statement is not modified in respect of our reliance on the interim financial information certified by the Management.

For **DELOITTE HASKINS & SELLS LLP**
Chartered Accountants
(Firm's Registration No. 117366W/W-100018)

Mehul Parekh
Partner
(Membership No. 121513)
(UDIN: 23121513BGYAEG4187)

Place: Mumbai
Date: August 03, 2023

**Deloitte
Haskins & Sells LLP**

ANNEXURE I TO THE INDEPENDENT AUDITOR'S REVIEW REPORT

(Referred to in paragraph 4 under Independent Auditor's Review Report of even date)

Parent

Piramal Pharma Limited

List of Subsidiaries

1. Piramal Dutch Holdings N.V.
2. Piramal Critical Care Italia, S.P.A
3. Piramal Critical Care Deutschland GmbH
4. Piramal Critical Care B.V.
5. Piramal Healthcare (Canada) Limited
6. Piramal Critical Care Limited
7. Piramal Critical Care South Africa (Pty) Ltd
8. Piramal Critical Care Pty. Ltd
9. Piramal Healthcare UK Limited
10. Piramal Healthcare Pension Trustees Limited
11. Piramal Healthcare Inc.
12. Piramal Critical Care Inc.
13. Piramal Pharma Inc.
14. PEL Pharma Inc.
15. Piramal Pharma Solutions Inc.
16. Ash Stevens LLC
17. Piramal Pharma Solutions (Dutch) B.V.
18. PEL Healthcare LLC
19. Piramal Pharma Japan GK
20. Piramal Pharma II Private Limited

List of Associates

1. Allergan India Private Limited
2. Yapan Bio Private Limited

